Why Standard Cancer Screening Falls Short
Conventional cancer screening protocols are remarkably narrow:
- Mammography screens for breast cancer
- Colonoscopy screens for colorectal cancer
- PSA tests screen for prostate cancer
- Low-dose CT screens for lung cancer (in high-risk smokers)
- Pap smears screen for cervical cancer
For the remaining 200+ types of cancer — pancreatic, ovarian, esophageal, gastric, liver, and many others — there is no standard recommended screening. These cancers are typically discovered when they produce symptoms — which is often Stage III or Stage IV.
The Galleri test was developed to address that gap.
How the Galleri Test Works
The Galleri test is a liquid biopsy — a blood test that detects circulating cell-free DNA (cfDNA) shed by cancer cells. When cells die, they release fragments of their DNA into the bloodstream. Cancer cells release DNA with distinct methylation patterns that differ from normal cells.
Galleri's technology analyzes these patterns to:
- Detect the presence of a cancer signal
- Identify the tissue of origin (predicting where the cancer is likely located)
The test screens for more than 50 cancer types simultaneously in a single blood draw.
What the Clinical Data Shows
The PATHFINDER study (published in The Lancet, 2023) evaluated Galleri in over 6,600 participants:
- In patients with a cancer signal detected, the tissue of origin prediction was accurate in approximately 88% of confirmed cases
- The test demonstrated greater sensitivity for later-stage cancers, but also detected a meaningful proportion of Stage I and Stage II cancers across cancer types
- False positive rates were low (approximately 0.9%)
The SUMMIT trial is currently ongoing, evaluating Galleri's impact on cancer stage at detection and cancer-related mortality.
Who Should Consider It
Galleri is currently recommended for adults over 50, or younger adults with elevated cancer risk due to:
- Family history of cancer
- Genetic predisposition (BRCA, Lynch syndrome, etc.)
- Prior cancer diagnosis
- Significant lifestyle risk factors
- Personal preference for comprehensive screening
It is not a replacement for established screening protocols. It is an additive layer — particularly valuable for cancer types with no existing standard screening.
Understanding a Positive Result
A positive Galleri result indicates a cancer signal was detected. It is not a cancer diagnosis.
Next steps following a positive result typically include:
- Imaging of the predicted tissue of origin
- Additional laboratory investigation
- Specialist consultation
Approximately 38% of positive results in the PATHFINDER study were confirmed as cancer on follow-up. The remainder were false positives or required ongoing monitoring.
This is why clinical context matters. A positive result is a directive to investigate — calmly, systematically, and promptly.
The Case for Proactive Screening
The five-year survival rate for pancreatic cancer caught at Stage I is approximately 42%. Caught at Stage IV, it's 3%.
For ovarian cancer: Stage I has a 92% five-year survival rate. Stage IV: 31%.
The biology doesn't lie. Stage matters enormously. And stage is determined by timing — which is determined by when you look.
The Galleri test gives us a way to look before the symptoms start.
PracticeRx offers the Galleri multi-cancer early detection test as part of our comprehensive preventative screening protocol. Ask about it at your next consultation.